Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linsitinib + bortezomib + dexamethasone
- Development stage
- Phase 2
- Lead developer
- Sling Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A three-drug combination therapy consisting of: - **Linsitinib** (OSI-906/ASP7487): a small molecule inhibitor of the insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR). - **Bortezomib**: a small molecule proteasome inhibitor. - **Dexamethasone**: a synthetic glucocorticoid corticosteroid. This regimen has been investigated in phase 1 trials for relapsed/refractory multiple myeloma. Linsitinib inhibits IGF-1R and IR, thereby blocking growth and survival signaling in tumor cells. Bortezomib inhibits the 26S proteasome, leading to cell cycle arrest and apoptosis in myeloma cells. Dexamethasone acts as an anti-inflammatory and immunosuppressive agent and is standard in myeloma regimens, enhancing the efficacy of other agents. In phase 1 trials, this combination demonstrated manageable toxicity and antimyeloma activity, especially in proteasome inhibitor-refractory patients[1][2][6][8].
- Other names
- linsitinib + bortezomib + dexamethasone
02
Targets
PSMB9 (Immunoproteasome subunit beta type-1i)PSMB5 (Proteasome subunit beta Type-5)GR (Glucocorticoid receptor)IGF-1R (Insulin-like growth factor 1 receptor)INSR (Insulin receptor)
Beyond the preview
Go deeper on linsitinib + bortezomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linsitinib + bortezomib + dexamethasone.